Application Dominance and Application Segmentation: Why the Oncology Segment Captures a 45% Share of the Small Interfering RNA Market
The success of the Small Interfering RNA Market is intrinsically tied to its therapeutic efficacy in high-need disease areas. Market Research Future data confirms that this trend is most pronounced in oncology, which currently commands the largest share growth, securing approximately 45% of the market in 2023. This dominance is a powerful signal to biopharmaceutical companies regarding where...
0 Commenti 0 condivisioni 0 Anteprima